UDK: 616.379-008.64-085.8
N. V. Rogova
Кафедра клинической фармакологии и интенсивной терапии ВолГМУ
Capacity of hepatic enzyme systems, such as isoenzymes of the cytochrome P-450, known as the CYPs is considered to be the main limitation factor for the pharmacokinetics of drugs, their drug-drug interactions and development of adverse drug reactions. The CYP 3A4 isoenzyme is involved in metabolism of about 50 % of drugs clinically used in treatment of patients with type II diabetes. TES-therapy is proved to boost the CYP 3A4 isoensyme activity in patients with type II diabetes. This will enable to influence the pharmacokinetics of drugs, prevent and treat undesirable drug reactions.
Diabetes mellitus, TES-therapy, СYP3A4, treatment of adverse drug reactions.
Рогова Наталья Вячеславовна - к.м.н., доцент кафедры клинической фармакологии и интенсивной терапии с курсами клинической фармакологии ФУВ, клинической аллергологии ФУВ, восстановительной терапии и курортологии ФУВ ВолГМУ, (8442) 43-30-60, 43-60-36, nvrog